CO2023011623A2 - Compuestos inhibidores de fgfr3 - Google Patents

Compuestos inhibidores de fgfr3

Info

Publication number
CO2023011623A2
CO2023011623A2 CONC2023/0011623A CO2023011623A CO2023011623A2 CO 2023011623 A2 CO2023011623 A2 CO 2023011623A2 CO 2023011623 A CO2023011623 A CO 2023011623A CO 2023011623 A2 CO2023011623 A2 CO 2023011623A2
Authority
CO
Colombia
Prior art keywords
inhibitory compounds
fgfr3 inhibitory
achondroplasia
fibrosis
fgfr3
Prior art date
Application number
CONC2023/0011623A
Other languages
English (en)
Inventor
Adedoyin David Abraham
Desta Doro Bume
Kevin Ronald Condroski
Andrew Karl Dilger
Robert Alan Hazlitt
Timothy Scott Kercher
Andrew Terrance Metcalf
Kaveri Balan Urkalan
Shane Michael Walls
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2023011623A2 publication Critical patent/CO2023011623A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona los compuestos de la fórmula: , para usar en el tratamiento de la esclerosis sistémica, la fibrosis (p. ej., fibrosis pulmonar), la acondroplasia, la displasia tanatofórica (p. ej., tipo I), la acondroplasia grave con retraso del desarrollo y acantosis nigricans (SADDAN), el síndrome de Muenke o el cáncer.
CONC2023/0011623A 2021-03-04 2023-09-01 Compuestos inhibidores de fgfr3 CO2023011623A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156527P 2021-03-04 2021-03-04
PCT/US2022/018644 WO2022187443A1 (en) 2021-03-04 2022-03-03 Fgfr3 inhibitor compounds

Publications (1)

Publication Number Publication Date
CO2023011623A2 true CO2023011623A2 (es) 2023-09-18

Family

ID=80937162

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0011623A CO2023011623A2 (es) 2021-03-04 2023-09-01 Compuestos inhibidores de fgfr3

Country Status (17)

Country Link
US (1) US11878976B2 (es)
EP (1) EP4301468A1 (es)
JP (1) JP7480438B2 (es)
KR (1) KR20230130170A (es)
CN (1) CN117120439A (es)
AR (1) AR125588A1 (es)
AU (1) AU2022229380A1 (es)
BR (1) BR112023015519A2 (es)
CA (1) CA3210594A1 (es)
CO (1) CO2023011623A2 (es)
CR (1) CR20230427A (es)
DO (1) DOP2023000176A (es)
EC (1) ECSP23066654A (es)
IL (1) IL304886A (es)
PE (1) PE20231563A1 (es)
TW (2) TW202402754A (es)
WO (1) WO2022187443A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240116932A1 (en) 2022-09-07 2024-04-11 Eli Lilly And Company Cocrystalline forms of fgfr3 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
ES2796377T3 (es) 2010-03-10 2020-11-26 Incyte Holdings Corp Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
CN101833512A (zh) 2010-04-22 2010-09-15 中兴通讯股份有限公司 一种内存回收方法及其装置
AU2012323399A1 (en) 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
US9376441B2 (en) 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
EP3298011B1 (en) * 2015-05-22 2021-11-17 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor receptor inhibitors
JP6751977B2 (ja) 2016-09-01 2020-09-09 南京薬捷安康生物科技有限公司 線維芽細胞増殖因子受容体の阻害剤及びそれらの使用
CN107315291B (zh) 2017-07-19 2020-06-16 深圳市华星光电半导体显示技术有限公司 一种goa显示面板及goa显示装置
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Also Published As

Publication number Publication date
JP7480438B2 (ja) 2024-05-09
CR20230427A (es) 2023-09-26
US11878976B2 (en) 2024-01-23
AR125588A1 (es) 2023-08-02
WO2022187443A1 (en) 2022-09-09
TW202402754A (zh) 2024-01-16
CA3210594A1 (en) 2022-09-09
EP4301468A1 (en) 2024-01-10
AU2022229380A1 (en) 2023-08-24
PE20231563A1 (es) 2023-10-03
BR112023015519A2 (pt) 2023-10-03
IL304886A (en) 2023-10-01
KR20230130170A (ko) 2023-09-11
TWI820622B (zh) 2023-11-01
TW202300491A (zh) 2023-01-01
US20230095122A1 (en) 2023-03-30
JP2023554598A (ja) 2023-12-28
CN117120439A (zh) 2023-11-24
ECSP23066654A (es) 2024-02-29
DOP2023000176A (es) 2023-09-29

Similar Documents

Publication Publication Date Title
CO2023011623A2 (es) Compuestos inhibidores de fgfr3
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
CY1126132T1 (el) Πυριδαζινονες ως αναστολεις parp7
CO2022015251A2 (es) Compuestos de 2,4-dioxopirimidina inhibidores de cd73
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
AR099854A1 (es) Derivados de quinaxolina con acción sobre tirosinquinasas
CL2020000950A1 (es) Potenciador para células t o células b que tienen función de memoria, inhibidor de recurrencia de tumor maligno, e inductor para inducir la función de memoria en células t o células b.
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
CL2020001719A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd (divisional solicitud 202000911)
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
NZ756408A (en) Methods for increasing blood plasma 2’-deoxyuridine (durd) and thymidylate synthase inhibition
BR112017022807A2 (pt) ?bomba submersível elétrica, e, coluna de bomba submersível elétrica?
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
WO2020115491A3 (en) Immune checkpoint inhibitor in combination with sonodynamic therapy
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
JP2019111093A5 (es)
EA202092909A1 (ru) Новый бензодиазепин, его производные и применение
CU20190019A7 (es) Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer
MX2021001870A (es) Metodo para tratar cancer pancreatico.
CL2018001986A1 (es) Placa de válvula de compuerta deslizante
EA201990443A1 (ru) Новое применение n,n-бис-2 -меркаптоэтилизофталамида
BR112021006298A2 (pt) composições e métodos para estabilizar coelenterazina e análogos e derivados da mesma